Abstract
Background: SARS-CoV-2 rapid antigen tests are an important public health tool.
Objective: To evaluate field performance of the BinaxNOW rapid antigen test (Abbott) compared with reverse transcriptase polymerase chain reaction (RT-PCR) for detecting infection with the Omicron variant of SARS-CoV-2.
Design: Cross-sectional surveillance study.
Setting: Free, walk-up, outdoor, urban community testing and vaccine site led by Unidos en Salud, serving a predominantly Latinx community highly impacted by COVID-19.
Participants: Persons seeking COVID-19 testing in January 2022.
Measurements: Simultaneous BinaxNOW and RT-PCR from nasal, cheek, and throat swabs, including cycle threshold (Ct) measures; a lower Ct value is a surrogate for higher amounts of virus.
Results: Among 731 persons tested with nasal swabs, there were 296 (40.5%) positive results on RT-PCR; 98.9% were the Omicron variant. BinaxNOW detected 95.2% (95% CI, 91% to 98%) of persons who tested positive on RT-PCR with a Ct value below 30, 82.1% (CI, 77% to 87%) of those who tested positive on RT-PCR with a Ct value below 35, and 65.2% (CI, 60% to 71%) of all who were positive on RT-PCR. Among 75 persons with simultaneous nasal and cheek swabs, BinaxNOW using a cheek swab failed to detect 91% (20 of 22) of specimens that were positive on BinaxNOW with a nasal swab. Among persons with simultaneous nasal and throat swabs who were positive on RT-PCR with a Ct value below 30, 42 of 49 (85.7%) were detected by nasal BinaxNOW, 23 of 49 (46.9%) by throat BinaxNOW, and 44 of 49 (89.8%) by either.
Limitation: Participants were a cross-sectional sample from a community-based sentinel surveillance site, precluding study of viral or symptom dynamics.
Conclusion: BinaxNOW detected persons with high SARS-CoV-2 levels during the Omicron surge, enabling rapid responses to positive test results. Cheek or throat swabs should not replace nasal swabs. As currently recommended, high-risk persons with an initial negative BinaxNOW result should have repeated testing.
Primary funding source: University of California, San Francisco.
【초록키워드】 COVID-19, public health, SARS-CoV-2, Vaccine, cross-sectional, variant, Infection, nasal, Symptom, omicron, RT-PCR, virus, Antigen, polymerase chain reaction, Rapid antigen tests, COVID-19 testing, Reverse transcriptase polymerase chain reaction, rapid antigen test, Surveillance, cycle threshold, swabs, Community, Ct value, Omicron variant, Swab, nasal swab, university, rapid response, Abbott, San Francisco, reverse transcriptase, Chain Reaction, Simultaneous, 95% CI, throat swabs, positive result, specimen, participant, Positive test, positive, throat swab, nasal swabs, transcriptase, surrogate, repeated, polymerase chain, Latinx community, initial, variant of SARS-CoV-2, Free, cheek, tested, detect, evaluate, impacted, Person, seeking, 【제목키워드】 SARS-CoV-2, Test, omicron, Rapid, reaction, chain, Site,